Halozyme Director Executes Scheduled Stock Sale Amidst Shifting Analyst Projections
Halozyme Therapeutics, Inc. (NASDAQ: HALO) recently saw insider activity following a transaction by one of its directors. On May 1, 2026, Bernadette Connaughton, a director at the biotechnology firm, sold common stock valued at $103,155. This sale involved 1,625 shares, which were priced at $63.48 per share during the transaction. The divestment wa…